Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos brasileiros de oftalmologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492014000600008 |
Resumo: | Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuvant medication (Group 1), 59 patients received intraoperative bevacizumab (Group 2) and 37 patients received intraoperative triamcinolone (4 mg/0.1 ml) (Group 3). Results: The mean logMAR [± standard deviation (SD)] BCVA improved from 0.82 (± 0.43) at baseline, to 0.14 (± 0.23) at 6-month follow-up (p<0.001) in Group 1; from 0.80 (± 0.48) to 0.54 (± 0.45) (p<0.001) in Group 2; and from 1.0 (± 0.40) to 0.46 (± 0.34) (p<0.001) in Group 3. The mean central subfield thickness increased from 263.57 µm (± 35.7) at baseline to 274.57 µm (± 48.7) at 6-month follow-up (p=0.088) in Group 1; from 316.02 µm (± 100.4) to 339.56 µm (± 145.3) (p=0.184) in Group 2; and from 259.18 µm (± 97.9) to 282.21 µm (± 87.24) (p=0.044) in Group 3. Conclusion: Diabetic patients may significantly benefit from cataract surgery. This study provides evidence to support the use of intravitreal triamcinolone or bevacizumab at the time of cataract surgery in cases with pre-existent diabetic macular edema or moderate-severe non-proliferative diabetic retinopathy. |
id |
CBO-2_b07628e4c0470dc462cae588c943ece1 |
---|---|
oai_identifier_str |
oai:scielo:S0004-27492014000600008 |
network_acronym_str |
CBO-2 |
network_name_str |
Arquivos brasileiros de oftalmologia (Online) |
repository_id_str |
|
spelling |
Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study GroupDiabetic retinopathyMacular edemaCataract extractionIntraoperative carePhacoemulsificationLens implantation, intraocularAntibodies, monoclonalMulticenter study Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuvant medication (Group 1), 59 patients received intraoperative bevacizumab (Group 2) and 37 patients received intraoperative triamcinolone (4 mg/0.1 ml) (Group 3). Results: The mean logMAR [± standard deviation (SD)] BCVA improved from 0.82 (± 0.43) at baseline, to 0.14 (± 0.23) at 6-month follow-up (p<0.001) in Group 1; from 0.80 (± 0.48) to 0.54 (± 0.45) (p<0.001) in Group 2; and from 1.0 (± 0.40) to 0.46 (± 0.34) (p<0.001) in Group 3. The mean central subfield thickness increased from 263.57 µm (± 35.7) at baseline to 274.57 µm (± 48.7) at 6-month follow-up (p=0.088) in Group 1; from 316.02 µm (± 100.4) to 339.56 µm (± 145.3) (p=0.184) in Group 2; and from 259.18 µm (± 97.9) to 282.21 µm (± 87.24) (p=0.044) in Group 3. Conclusion: Diabetic patients may significantly benefit from cataract surgery. This study provides evidence to support the use of intravitreal triamcinolone or bevacizumab at the time of cataract surgery in cases with pre-existent diabetic macular edema or moderate-severe non-proliferative diabetic retinopathy. Conselho Brasileiro de Oftalmologia2014-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492014000600008Arquivos Brasileiros de Oftalmologia v.77 n.6 2014reponame:Arquivos brasileiros de oftalmologia (Online)instname:Conselho Brasileiro de Oftalmologia (CBO)instacron:CBO10.5935/0004-2749.20140089info:eu-repo/semantics/openAccessGallego-Pinazo,RobertoDolz-Marco,RosaBerrocal,MariaWu,LihtehMaia,MauricioSerrano,MartínAlezzandrini,ArturoArévalo,J. FernandoDíaz-Llopis,Manueleng2015-04-10T00:00:00Zoai:scielo:S0004-27492014000600008Revistahttp://aboonline.org.br/https://old.scielo.br/oai/scielo-oai.phpaboonline@cbo.com.br||abo@cbo.com.br1678-29250004-2749opendoar:2015-04-10T00:00Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)false |
dc.title.none.fl_str_mv |
Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group |
title |
Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group |
spellingShingle |
Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group Gallego-Pinazo,Roberto Diabetic retinopathy Macular edema Cataract extraction Intraoperative care Phacoemulsification Lens implantation, intraocular Antibodies, monoclonal Multicenter study |
title_short |
Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group |
title_full |
Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group |
title_fullStr |
Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group |
title_full_unstemmed |
Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group |
title_sort |
Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group |
author |
Gallego-Pinazo,Roberto |
author_facet |
Gallego-Pinazo,Roberto Dolz-Marco,Rosa Berrocal,Maria Wu,Lihteh Maia,Mauricio Serrano,Martín Alezzandrini,Arturo Arévalo,J. Fernando Díaz-Llopis,Manuel |
author_role |
author |
author2 |
Dolz-Marco,Rosa Berrocal,Maria Wu,Lihteh Maia,Mauricio Serrano,Martín Alezzandrini,Arturo Arévalo,J. Fernando Díaz-Llopis,Manuel |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Gallego-Pinazo,Roberto Dolz-Marco,Rosa Berrocal,Maria Wu,Lihteh Maia,Mauricio Serrano,Martín Alezzandrini,Arturo Arévalo,J. Fernando Díaz-Llopis,Manuel |
dc.subject.por.fl_str_mv |
Diabetic retinopathy Macular edema Cataract extraction Intraoperative care Phacoemulsification Lens implantation, intraocular Antibodies, monoclonal Multicenter study |
topic |
Diabetic retinopathy Macular edema Cataract extraction Intraoperative care Phacoemulsification Lens implantation, intraocular Antibodies, monoclonal Multicenter study |
description |
Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuvant medication (Group 1), 59 patients received intraoperative bevacizumab (Group 2) and 37 patients received intraoperative triamcinolone (4 mg/0.1 ml) (Group 3). Results: The mean logMAR [± standard deviation (SD)] BCVA improved from 0.82 (± 0.43) at baseline, to 0.14 (± 0.23) at 6-month follow-up (p<0.001) in Group 1; from 0.80 (± 0.48) to 0.54 (± 0.45) (p<0.001) in Group 2; and from 1.0 (± 0.40) to 0.46 (± 0.34) (p<0.001) in Group 3. The mean central subfield thickness increased from 263.57 µm (± 35.7) at baseline to 274.57 µm (± 48.7) at 6-month follow-up (p=0.088) in Group 1; from 316.02 µm (± 100.4) to 339.56 µm (± 145.3) (p=0.184) in Group 2; and from 259.18 µm (± 97.9) to 282.21 µm (± 87.24) (p=0.044) in Group 3. Conclusion: Diabetic patients may significantly benefit from cataract surgery. This study provides evidence to support the use of intravitreal triamcinolone or bevacizumab at the time of cataract surgery in cases with pre-existent diabetic macular edema or moderate-severe non-proliferative diabetic retinopathy. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492014000600008 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492014000600008 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.5935/0004-2749.20140089 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Conselho Brasileiro de Oftalmologia |
publisher.none.fl_str_mv |
Conselho Brasileiro de Oftalmologia |
dc.source.none.fl_str_mv |
Arquivos Brasileiros de Oftalmologia v.77 n.6 2014 reponame:Arquivos brasileiros de oftalmologia (Online) instname:Conselho Brasileiro de Oftalmologia (CBO) instacron:CBO |
instname_str |
Conselho Brasileiro de Oftalmologia (CBO) |
instacron_str |
CBO |
institution |
CBO |
reponame_str |
Arquivos brasileiros de oftalmologia (Online) |
collection |
Arquivos brasileiros de oftalmologia (Online) |
repository.name.fl_str_mv |
Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO) |
repository.mail.fl_str_mv |
aboonline@cbo.com.br||abo@cbo.com.br |
_version_ |
1754209028215406592 |